title: Monitoring of anthracycline-induced cardiotoxicity.
abstract: OBJECTIVE
  To review the literature regarding the appropriate monitoring for anthracycline-induced cardiotoxicity.
  
  
  METHODS
  A MEDLINE search of the literature was performed (1966-August 2007). Search terms included anthracycline, cardiotoxicity, and monitoring. Additional references were identified through bibliographic reviews.
  
  
  RESULTS
  Anthracycline medications are effective in the treatment of many malignancies but their use is limited by their associated cardiotoxicity. The focus of anthracycline-induced cardiotoxicity prevention has been on monitoring cardiac function during treatment; however, a consensus on the most appropriate way to monitor patients is not available. Most guidelines lack specific details on the appropriate methods of cardiac evaluation and schedule. One guideline that does provide specific recommendations on both the method of evaluation and schedule has been criticized for being too restrictive, costly, and lacking in evidentiary support. The literature is insufficient in evaluation of the predictive value of cardiac function monitoring by echocardiography or radionuclide angiography during anthracycline therapy and the future development of cardiotoxicity, the necessity of baseline cardiac function monitoring, the optimal follow-up cardiac evaluation schedule, and the addition of risk stratification to monitoring schemes.
  
  
  CONCLUSIONS
  Although guidelines are inadequate to predict and prevent anthracycline-induced cardiotoxicity, until further research is available, following one of the existing guidelines to monitor for this adverse effect is a practical solution.
authors: Department of Pharmaceutical Services, William Beaumont Hospital, Royal Oak, MI, USA. jannazzo@gmail.com
authors: Abigail
authors: A
authors: Jannazzo
authors: Janet
authors: J
authors: Hoffman
authors: Mark
authors: M
authors: Lutz
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D016903:Drug Monitoring / Q000379:methods; D004452:Echocardiography / Q000379:methods; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D017410:Practice Guidelines as Topic; D011875:Radionuclide Angiography / Q000379:methods; D018570:Risk Assessment
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic